Who Pays My Doctor?

Healthcare provider profile · identity verified

Benjamin R Marks, M.D./PH.D.

Allopathic & Osteopathic Physicians|Dermatology · GLENVIEW, IL · NPI 1407086317

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Benjamin R Marks, M.D./PH.D. received $2,133.09 in general payments during 2025 across 233 reported records.

Arcutis Biotherapeutics, Inc. accounted for 33.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 12 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$2,133.09

233 reported records · 8 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Arcutis Biotherapeutics, Inc. Unresolved — no canonical attribution shown $723.6133.9%862025
Janssen Biotech, Inc. Unresolved — no canonical attribution shown $536.0125.1%662025
Novartis Pharmaceuticals Corporation Unresolved — no canonical attribution shown $272.2512.8%252025
Regeneron Healthcare Solutions, Inc. Unresolved — no canonical attribution shown $238.0211.2%152025
Lilly USA, LLC Unresolved — no canonical attribution shown $186.468.7%222025
UCB, Inc. Unresolved — no canonical attribution shown $147.016.9%172025
Incyte Corporation Unresolved — no canonical attribution shown $15.160.7%12025
ABBVIE INC. Unresolved — no canonical attribution shown $14.570.7%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$2,047.62232
Education$85.471

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
Zoryve
Normalized: zoryve		 Drug Arcutis Biotherapeutics, Inc. $723.61 86 2025
Source payment records
TREMFYA
Normalized: tremfya		 Drug Janssen Biotech, Inc. $536.01 66 2025
Source payment records
COSENTYX
Normalized: cosentyx		 Drug Novartis Pharmaceuticals Corporation $272.25 25 2025
Source payment records
DUPIXENT
Normalized: dupixent		 Biological Regeneron Healthcare Solutions, Inc. $238.02 15 2025
Source payment records
EBGLYSS
Normalized: ebglyss		 Drug Lilly USA, LLC $170.49 20 2025
Source payment records
Bimzelx
Normalized: bimzelx		 Biological UCB, Inc. $147.01 17 2025
Source payment records
SIMPONI
Normalized: simponi		 Biological Janssen Biotech, Inc. $146.80 15 2025
Source payment records
SIMPONI ARIA
Normalized: simponi aria		 Biological Janssen Biotech, Inc. $146.80 15 2025
Source payment records
STELARA
Normalized: stelara		 Biological Janssen Biotech, Inc. $146.80 15 2025
Source payment records
TALTZ
Normalized: taltz		 Drug Lilly USA, LLC $99.30 10 2025
Source payment records
OPZELURA
Normalized: opzelura		 Drug Incyte Corporation $15.16 1 2025
Source payment records
RINVOQ
Normalized: rinvoq		 Biological ABBVIE INC. $14.57 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

BrandGenericClaimsBeneficiaries
KetoconazoleKetoconazole428203
Triamcinolone AcetonideTriamcinolone Acetonide232195
Clobetasol PropionateClobetasol Propionate10664
SpironolactoneSpironolactone9221
MinoxidilMinoxidil8823
Mometasone FuroateMometasone Furoate8162
Doxycycline HyclateDoxycycline Hyclate6930
NystatinNystatin6245
CiclopiroxCiclopirox5326
TacrolimusTacrolimus4632
FluorouracilFluorouracil4337
Clindamycin PhosphateClindamycin Phosphate4122
ValacyclovirValacyclovir Hcl4021
MetronidazoleMetronidazole3022
PrednisonePrednisone2817
Humira(Cf) PenAdalimumab27suppressed
MupirocinMupirocin2621
Azelaic AcidAzelaic Acid25suppressed
Cosentyx Sensoready PenSecukinumab25suppressed
Mycophenolate MofetilMycophenolate Mofetil24suppressed
Econazole NitrateEconazole Nitrate2216
Cosentyx (2 Syringes)Secukinumab20suppressed
AcitretinAcitretin19suppressed
HydrocortisoneHydrocortisone1914
CephalexinCephalexin1818
Taltz AutoinjectorIxekizumab17suppressed
Alclometasone DipropionateAlclometasone Dipropionate1612
Betamethasone ValerateBetamethasone Valerate1412
Dupixent SyringeDupilumab13suppressed
GabapentinGabapentin13suppressed
MethotrexateMethotrexate Sodium13suppressed
Hydroxychloroquine SulfateHydroxychloroquine Sulfate12suppressed
EnbrelEtanercept11suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $2,133.09 · 233 records Arcutis Biotherapeutics, Inc. Bimzelx, COSENTYX, DUPIXENT, EBGLYSS, OPZELURA, RINVOQ, SIMPONI, SIMPONI ARIA, STELARA, TALTZ, TREMFYA, Zoryve — —
2024 — — — — Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error